CMS has proposed two new models aimed at curbing Medicare drug spending by linking payments to international benchmarks. The proposals — GUARD for Part D drugs and GLOBE for Part B — are the latest in the CMS Innovation Center’s…
Pharmacy
As healthcare increasingly moves toward ambulatory facilities, pharmacy departments at several health systems are expanding into the outpatient space, including Walnut Creek, Calif.-based John Muir Health. In 2024, John Muir opened a cancer infusion center to centralize care for oncology…
As health systems look to expand service lines, improve access and take on more complex medication management, pharmacy leaders say workforce shortages are determining where growth is possible — and where it must wait. Across community, acute and specialty settings,…
The Trump administration finalized agreements Dec. 19 with nine pharmaceutical manufacturers to offer U.S. patients prescription drug prices aligned with the lowest rates paid by other developed nations. The companies — Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences,…
Hospitals and health systems face mounting pharmacy-related challenges across access, affordability, workforce and supply chain, according to the American Hospital Association’s 2026 Environmental Scan. The report, published Dec. 3, was designed as a roadmap for hospital leaders and covers financial…
Advertisement
Mark Cuban Cost Plus Drug Co. has added Vegzelma, a biosimilar indicated for six cancer types, to its marketplace for hospitals and other healthcare providers. The company plans to expand its biosimilar offerings amid growing demand for biologics among health…
The Pennsylvania House passed legislation Dec. 16 to preserve access to pharmacist-administered vaccines, even if federal recommendations change. The bill would allow pharmacists to provide vaccines based on guidance from state authorities — including the Pennsylvania Department of Health and…
All community and independent pharmacies in the Optum Rx network have transitioned to a cost-based reimbursement model aimed at improving payment transparency and stability. The shift follows new agreements with three pharmacy services administration organizations, which represent more than 17,000…
The FDA has granted full approval to rucaparib (Rubraca) for adults with BRCA-mutated metastatic castration-resistant prostate cancer. The decision is based on a confirmatory analysis of a randomized trial of 405 patients who had progressed on prior androgen receptor pathway…
Some U.S. hospitals and health systems are marking up generic cancer drugs by more than five times their commercial rates, Bloomberg reported Dec. 17. Bloomberg analyzed data from the price transparency platform Turquoise Health. Of the more than 1,700 hospitals and eight…